Considerations in the treatment of relapsing-remitting multiple sclerosis

Neurology

Volumn 58, Issue 8 SUPPL. 5, 2002, Pages

  Calabresi, Peter A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE;

CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DYSPNEA; FLU LIKE SYNDROME; HEART PALPITATION; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RELAPSE; REVIEW; SYMPTOMATOLOGY;

EID: 0037161256     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.58.8_suppl_4.s10     Document Type: Review

References (107)

1. Burden of illness of multiple sclerosis: Part II: Quality of life
2. Cost and health related quality of life consequences of multiple sclerosis
3. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom
4. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
5. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
6. Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
7. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
8. Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis
9. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
10. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
11. Disease management consensus statement
12. Consensus Statement of the Canadian MS Clinics Network on: The use of disease modifying agents in multiple sclerosis
13. Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis
14. Axonal transection in the lesions of multiple sclerosis
15. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis
16. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action
17. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers
18. Observations on differences between interferons used to treat multiple sclerosis
19. Recombinant human interferon-beta-1a (Rebif) vs recombinant interferon-beta-1b (Betaseron) in healthy volunteers
20. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
21. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
22. Effect of interferon beta-1b in MS. Assessment of annual accumulation of PD/T2 activity on MRI
23. Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure
24. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
25. Treatment with interferon beta-1b improves quality of life in multiple sclerosis
26. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
27. Extended observations on MS patients treated with IM interferon beta-1a (Avonex): Implications for modern MS trials and therapeutics
28. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis
29. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
30. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
31. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis
32. Evidence for interferon beta-1a dose response in relapsing-remitting MS
33. The EVIDENCE Study: Data summary
34. A multicenter randomized trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis
35. Randomised, double-blind, placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves
36. PRISMS-4: Long-term efficacy of interferon beta-1a in relapsing MS
37. Magnetic resonance imaging results of the PRISMS trial: A randomized double-blind, placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis
38. Effect of early IFN treatment on conversion to definite MS: A randomized study
39. Managing side effects of interferon beta in patients with relapsing-remitting multiple sclerosis
40. Ibuprofen treatment vs gradual introduction of interferon beta-1b in patients with MS
41. Low-dose steroids reduce flu-like symptoms at the initiation of IFN beta-1b in relapsing-remitting MS
42. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon beta-1b treatment in patients with multiple sclerosis
43. Multiple sclerosis: Side effects of interferon beta therapy and their management
44. Autoimmune events during interferon beta-1b treatment for multiple sclerosis
45. Interferon treatment for multiple sclerosis: Autoimmune complications may be lethal
46. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b
47. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first 3 years
48. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b
49. Neutralizing and binding anti-interferon beta (IFN beta) antibodies. A comparison between IFN beta-1a and IFN beta-1b treatment in multiple sclerosis
50. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
51. Binding of random copolymers of three amino acids to class II MHC molecules
52. Glatirameer acetate (copolymer-1)-specific, human T cell lines: Cytokine profile and suppression of the T cell lines reactive against myelin basic protein
53. Glatiramer acetate (Copaxone) induces degenerate, TH2-polarized immune responses in patients with multiple sclerosis
54. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
55. Mechanisms of action of glatiramer acetate in multiple sclerosis
56. Mechanisms of immunomodulation by glatiramer acetate
57. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
58. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
59. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS
60. Effect of copolymer 1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis
61. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
62. The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
63. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates
64. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes"
65. Short-term brain volume change in relapsing-remitting multiple sclerosis: Effect of glatiramer acetate and implications
66. Antibodies to copolymer 1 do not interfere with its clinical effect
67. Humoral responses to copolymer 1 in multiple sclerosis patients: Preferential production of IgG1 over IgG2
68. Antibodies to copolymer 1 do not interfere with its therapeutic effect
69. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imaging lesions
70. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: Their contribution in understanding multiple sclerosis evolution
71. Adherence to injection therapy in multiple sclerosis: Patients survey
72. Safety and tolerability of glatiramer acetate for injection (formerly known as copolymer 1) in the treatment of multiple sclerosis patients previously treated with interferon beta-1b
73. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive
74. Benefit of Copaxone demonstrated in patients with relapsing-remitting multiple sclerosis (RRMS) previously treated with interferon
75. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects
76. Intravenous methylprednisolone for multiple sclerosis in relapse
77. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
78. Randomized trial comparing two different high doses of methylprednisolone in MS. A clinical and MRI study
79. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
80. Effects of steroids on Gd-enhancing lesions before and during recombinant beta interferon-1a treatment in relapsing-remitting multiple sclerosis
81. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis
82. Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology
83. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS
84. Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis
85. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
86. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, randomised, observer-blind phase III trial: Clinical results and 3-year follow up
87. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
88. Multiple sclerosis trials
89. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses
90. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis
91. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
92. Overview of azathioprine in multiple sclerosis
93. New treatments and azathioprine in multiple sclerosis
94. ERAZISMUS: Early azathioprine vs beta-interferon treatment in multiple sclerosis: Results of a pilot safety study
95. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
96. An open-label trial of combination MS therapy using IFN beta-1a and oral methotrexate 20 mg weekly
97. An open label trial of combination therapy with IFN beta-1a and oral methotrexate in MS
98. Effect of open-label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis
99. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
100. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis
101. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
102. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis
103. Effect of glatiramer acetate (Copaxone) given orally in human patients: Interleukin-10 production during a phase 1 trial
104. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis
105. Ingested IFN-alpha. Results of a pilot study in relapsing-remitting MS
106. A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS